Jerry Rosenblatt, Ph.D.

Jerry Rosenblatt, Ph.D.

Dr. Rosenblatt is a Partner at Foster Rosenblatt, an international market research and advisory firm, exclusively focused on life sciences. Dr. Rosenblatt is a former Professor of Marketing, Associate Dean and Director of the MBA and Executive Development Programs at the John Molson School of Business, Concordia University, Montreal. He is a former Professor of Marketing and graduate of McGill University, one of Canada’s leading academic institutions. Dr. Rosenblatt was the Global Practice Leader, Forecasting and Opportunity Assessment practice for IMS Consulting (a leading healthcare research company), with over 25 years of experience as marketing advisor to pharmaceutical companies.

Michael Bartholomew, MS

Mr. Michael Bartholomew is the EVP and Chief Commercial Officer at Promaxo. He has broad therapeutic experience across nearly twenty diseases covering large and small molecules, medical devices and diagnostics. Michael manages the go to market strategy, voice of customer, partner relationships and tactical implementation relating to corporate

infrastructure. Prior to Promaxo, Michael was a Principal at Porzio Life Sciences, as well as Vice President of Sales & Marketing for Dohmen Life Science Service, where he developed and launched several commercial initiatives achieving sustained sales growth. Before Dohmen, he served in various sales and brand leadership positions for Pfizer, Pharmacia and Baxter. Michael proudly served in the US Air Force as a decorated combat aviator, where he achieved the rank of Captain. He received his Masters of Science in Administration from Central Michigan University and his Bachelor of Arts in Economics from Indiana University.

Jon Saxe, J,D. , LLM

Mr. Saxe has served as a director of over 25 companies and at present is a director of three public companies, Durect Corporation (NASDAQ: DRRX), VistaGen (VSTA.OB) and SciClone Pharmaceuticals, Inc. (CNASDAQ:SCLN) and private companies A-Cube, Arbor Vita, Arcuo Medical, EB Vac, Lumos Pharma and Vytacera.

He is Chairman of the Board of Lumos Pharma, SciClone, Vista Gen and Vytacera. He was President of PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) (NASDAQ: PDLI) from 1995 to 1999. In 1999-2000 he was E-I-R at Institutional Venture Partners. From 1993 to 1995, Mr. Saxe was Principal of Saxe Associates, Inc., consultants to venture capital firms and biotechnology, diagnostic and pharmaceutical companies.

From 1989 to 1993 he was the President and CEO of Synergen, Inc., a biotechnology company purchased by Amgen. Prior to then Mr. Saxe was Vice President, Licensing and Corporate Development and Head of Patent Law for Hoffmann-LaRoche Inc., where he worked for 29 years. Mr. Saxe received a B.S.Ch,E. from Carnegie Mellon University, his J.D. from George Washington University School of Law, his LL.M. from New York University School of Law and a Certificate in Business Administration from Duke University.

Paul M Russo, Ph.D

Dr. Russo is the Founder & Chairman  Kyto Technologies and Life sciences Inc., a publicaly traded investment company. .  Dr. Russo was the founder and GEO Semiconductor. Dr. Russo also serves as a Director of Beam Semiconductor InBay Technologies and several other technology and life science start-ups (Dynamount, Illuminati, Exodos and others). Dr. Russo is heavily involved with the Band of Angels and other similar organizations which review over 1,000 start-ups’ business plans per year. He is also a Board Advisor to BWG, LLC. Dr. Russo has served as an outside director of ATI Technologies from 2001 through its acquisition by AMD in 2006.

Dr. Russo received his B.Eng. from McGill University (Canada) and his M.Sc. and Ph.D. in EECS from UC Berkeley. He holds eight U.S. patents, is a fellow of IEEE and has received numerous RCA and industry awards, including the IEEE Centennial Medal and the 2006 Tech Pioneer Award from the World Economic Forum.

Crist J. Frangakis

Crist Frangakis is a founder and the CEO of Achelios Therapeutics. He has over 25 years of experience in pharmaceutical research and development, licensing, and business development. He led the discovery and development of several cardiovascular and metabolic drugs, serving as scientist and section head of research at Burroughs Welcome and Glaxo. In addition, Crist had responsibility for pharmaceutical licensing and corporate development for 13 years at Johnson & Johnson and Bayer and closed on several successful major partnering deals. He received his Ph.D. in pharmacology from the University of Arizona and a B.S. in chemistry from South Carolina. Crist is an author of over 70 publications published in peer-refereed journals and 15 issued and pending patents.